KITS Eyecare Ltd. has announced an upward revision to its Q3 2024 revenue guidance, exceeding the previously projected range of $39 million to $41 million. This revision follows a record-breaking week of sales, reaching approximately $3.5 million for the week ending August 31, 2024. The company attributes this strong performance to increased demand and improved operational efficiency.
Lam Research Corporation (NASDAQ: LRCX) reported impressive financial results for the third quarter of 2024, beating analyst estimates for both earnings per share (EPS) and revenue. The company reported an EPS of $7.79, exceeding the consensus estimate of $7.29 by a significant margin of $0.50. Revenue for the quarter reached $3.79 billion, surpassing the consensus estimate of $3.72 billion. Lam Research also provided guidance for the fourth quarter of 2024, projecting revenue between $3.50 billion and $4.10 billion, slightly below the analyst consensus of $3.77 billion.
